Selventa CEO appointed to MIT scientific advisory board
This article was originally published in Scrip
Dr David de Graaf, CEO and president of Selventa, a personalised healthcare company, has been appointed a scientific advisory board member for the Massachusetts Institute of Technology's Center for Cancer Systems Biology (CCSB) in the National Cancer Institute's Integrative Cancer Biology Program. CCSB focuses on developing and implementing computational models to analyse cancer as a complex biological system, with the goal of advancing the technology and the understanding needed to find cures. Dr de Graaf is also on the scientific advisory board of the Swiss Institute of Bioinformatics.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.